



Provepharm announces that its Japanese partner Daiichi Sankyo, Co. Ltd., has received approval for the marketing in Japan of the Methylene Blue Injection medicinal product, made out of Proveblue® Methylene Blue active substance

Daiichi Sankyo will resolve the unmet medical need for an approved methylene blue injectable drug in Japan

Proveblue® is the patented grade of Methylene blue by Provepharm

Marseille, France, January 7th 2015 – Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has received approval for the development and marketing in Japan of the injectable Methylene Blue medicinal product made out of Provepharm's Proveblue® Methylene Blue active substance. Daiichi Sankyo had filed this application for marketing authorization with the Japanese health authorities in March 2014.

Provepharm has licensed exclusive rights to Daiichi Sankyo to develop and market its medicinal product in Japan. Injectable Methylene Blue has already been approved by the European Medicines Agency for the acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia. It is traded in Europe as "Methylthioninium Chloride Proveblue 5 mg/ml, Solution for Injection".

Methylene Blue is one of the agents publicly offered for development by the Review Committee on Unapproved Drugs and Indications with High Medical Needs set up by the Ministry of Health, Labour and Welfare in Japan. Daiichi Sankyo committed to making this drug available to Japanese patients.

About methaemoglobinaemia

Methaemoglobinaemia is a disorder characterized by an abnormal amount of methaemoglobin in the blood, leading to an inability to release oxygen to body tissue effectively. The disorder can be inherited or acquired after exposure to certain chemicals or drugs like anaesthetics, certain antibiotics and nitrites that are used in the preservation of food.

About Provepharm

Provepharm is a subsidiary of the Provence Technologies Group that is specialized in the development and commercialization of pharmaceutical drug products derived from active pharmaceutical ingredients (APIs) synthesized and patented by its parent company. Anticipating the pharmaceutical industry's needs, Provepharm adopted a strategy of repositioning and rehabilitating known compounds in new indications. This development strategy was designed to cater

for the growing demand for APIs that must comply with current quality demands and the first compound offered is Methylene Blue.

For more information, please visit www.provepharm.com

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, dyslipidemia and bacterial infections used by patients around the world, the Group has also launched treatments for thrombotic disorders and is building new product franchises. Furthermore, Daiichi Sankyo research and development is focused on bringing forth novel therapies in oncology and cardiovascular-metabolic diseases, including biologics. The Daiichi Sankyo Group has created a "Hybrid Business Model," to respond to market and customer diversity and optimize growth opportunities across the value chain.

For more information, please visit: www.daiichisankyo.com

Contact Provepharm Christian Neumann Director of Business Development and Licensing christian.neumann@provepharm.com Tel : +33 6 20 68 54 23	Media Contacts Andrew Lloyd & Associates Agnès Kempf / agnes@ala.com Sarah Morgan / sarah@ala.com Tel : +44 1273 675 100 Tel : +33 1 56 54 07 00
---	--